Finance

Lists
EWTX:NASDAQ
Edgewise Therapeutics Inc
41,11 USD
-0,70%
(-0,29) 1D
5-окт., 11:29:50 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EWTX...
Open
41,55 USD
High
41,79 USD
Low
40,32 USD
Mkt. cap
4,46 млд
Avg. vol.
1,48 млн
Volume
439,72 миң
52-wk high
48,51 USD
52-wk low
14,25 USD
EPS
-1,85 USD
Beta
0,35
Shares outstanding
108,60 млн
No. of employees
127
Open
41,55 USD
High
41,79 USD
Low
40,32 USD
Mkt. cap
4,46 млд
Avg. vol.
1,48 млн
Volume
439,72 миң
52-wk high
48,51 USD
52-wk low
14,25 USD
EPS
-1,85 USD
Beta
0,35
Shares outstanding
108,60 млн
No. of employees
127
News stories
From web sources and news partners
About Edgewise Therapeutics Inc
CEO-
Employees127
Founded2017
HeadquartersБоулдер, Колорадо, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websiteedgewisetx.com
Analyst ratings
Based on 11 analysts giving stock ratings to EWTX in the past 3 months
Strong buy
Buy
9
Hold
2
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for EWTX in the last 3 months.
Highest
Current 41,11 USD
60,00 USD (+45,95%)
Average
50,89 USD (+23,79%)
Lowest
36,00 USD (-12,43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Laura Chico
Wedbush
Buy
Maintained
53,00 USD
+28,9%
09/23/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
-
-
09/23/2026
Paul Choi
Goldman Sachs
Hold
Maintained
36,00 USD
-12,4%
09/22/2026
Leonid Timashev
RBC Capital
Buy
Maintained
59,00 USD
+43,5%
09/22/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
-
-
09/23/2026
Lander Egana Gorrono
H.C. Wainwright
Buy
Reiterated
57,00 USD
+38,7%
09/23/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
60,00 USD
+45,9%
08/20/2026
James Condulis
Stifel Nicolaus
Hold
Maintained
36,00 USD
-12,4%
08/11/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
55,00 USD
+33,8%
08/07/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
45,00 USD
+9,5%
08/06/2026
Mazahir Alimohamed
Oppenheimer
Buy
Initiated
51,00 USD
+24,1%
07/09/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
51,00 USD
+24,1%
07/06/2026
Unknown Analyst
Guggenheim
Buy
Maintained
41,00 USD
-0,3%
06/02/2026
Martin Auster
Raymond James
Buy
Reiterated
66,00 USD
+60,5%
06/01/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
20,00 USD
-51,4%
05/11/2026
David Nierengarten
Wedbush
Buy
Maintained
46,00 USD
+11,9%
05/08/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
51,00 USD
+24,1%
02/09/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,53 USD / -0,47 USD
-12,16%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
37,48 млн
43,59 млн
42,65 млн
47,55 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,38 млн
12,38 млн
11,46 млн
14,40 млн
Operating expense
46,86 млн
55,98 млн
54,12 млн
61,94 млн
Total operating expenses
46,86 млн
55,98 млн
54,12 млн
61,94 млн
Operating income
-46,86 млн
-55,98 млн
-54,12 млн
-61,94 млн
Other non operating income
-
-
-
-
EBT including unusual items
-40,67 млн
-50,22 млн
-49,01 млн
-57,33 млн
EBT excluding unusual items
-40,67 млн
-50,22 млн
-49,01 млн
-57,33 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-40,67 млн
-50,22 млн
-49,01 млн
-57,33 млн
Net profit margin
-
-
-
-
Earnings per share
-0,39
-0,47
-0,46
-0,53
Interest and investment income
6,19 млн
5,76 млн
5,10 млн
4,62 млн
Interest expense
-
-
-
-
Net interest expenses
6,19 млн
5,76 млн
5,10 млн
4,62 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-46,34 млн
-55,45 млн
-53,58 млн
-61,40 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору